癌症奈米技术市场－全球产业规模、份额、趋势、机会、预测：按类型、应用、最终用户、地区和竞争对手划分，2021-2031年

全球癌症奈米技术市场预计将从 2025 年的 380.5 亿美元大幅成长至 2031 年的 650.5 亿美元，复合年增长率为 9.35%。

该领域致力于利用奈米装置和颗粒实现对恶性肿瘤的高精度诊断、成像和治疗。其主要成长要素包括：迫切需要标靶药物递送系统以最大程度地降低传统化疗相关的全身毒性，以及早期检测能力日益重要。癌症发生率的上升进一步推动了这一成长趋势。根据美国癌症协会预测，美国新增癌症病例数预计在2024年首次超过200万例，凸显了奈米医学在改善治疗效果方面的迫切需求。

儘管取得了这些进展，但由于研发和治疗高成本，市场仍面临许多挑战，这构成了主要的进入门槛。此外，奈米材料安全性的监管复杂性也常延长核准流程。患者的经济负担十分沉重；根据美国癌症研究协会 (AACR) 2024 年的一份报告，美国超过 40% 的癌症患者在开始治疗后的短短两年内就会耗尽毕生积蓄。这种经济负担严重阻碍了这些先进技术的广泛应用，并可能限制整体市场成长。

市场驱动因素

推动市场加速发展的主要动力之一是製药业内部日益增多的策略联盟，这些联盟正在加速复杂奈米药物平台的商业化进程。领先的製药公司正积极寻求併购，将先进的标靶递送机制整合到其癌症治疗产品线中，确保临床成功所需的技术基础。这些联盟使每家公司都能利用其独特的合成生物学和偶联技术来提高治疗的精确度。强生公司扩展其标靶癌症治疗能力就清晰地展现了这种整合趋势。 2024年1月，强生公司宣布收购Ambrax公司，双方已达成一项价值约20亿美元的最终协议，收购Ambrax BioPharma公司用于新一代抗体药物偶联物（ADC）的专有平台。

同时，政府和私人部门对研发投入的激增，正成为诊断和治疗奈米技术创新发展的关键催化剂。公共部门的努力在降低早期技术风险以及支持旨在透过先进成像技术改善肿瘤可视化和手术效果的计划发挥着至关重要的作用。近期一项旨在创新癌症手术的联邦津贴反映了这种资金投入。根据白宫2024年9月发布的一份情况说明书，美国高级医学研究计画署（ARPA-H）向一个开发新技术（例如用于提高手术精度的显微成像系统）的团队拨款1.5亿美元。这笔资金的流入是为了回应由长期流行病学预测驱动的日益增长的全球需求。世界卫生组织（WHO）在2024年报告称，国际癌症研究机构（IARC）预测，到2050年，全球癌症新增病例将超过3500万例，这凸显了对可扩展奈米技术解决方案的迫切需求。

市场挑战

全球癌症奈米技术市场的扩张直接受到研发和治疗相关高昂成本的限制，这些成本构成了巨大的财务障碍。奈米颗粒的製造需要复杂的工程技术和精密製造工艺，导致其研发成本远高于传统药物。这些资本密集要求阻碍了中小型生物技术公司的投资，增加了现有公司的财务风险，并延缓了有前景的奈米药物从临床试验到商业化的进程。

因此，这些飙升的研发成本最终会转嫁到市场价格上，这对患者和医疗保健系统都带来了沉重的经济负担。这种经济负担限制了先进奈米疗法的普及，因为保险公司和公共卫生计画难以将这些昂贵的疗法纳入现有预算。根据欧洲製药工业协会联合会（EFPIA）统计，2023年欧洲癌症治疗的直接成本达到1,460亿欧元，凸显了医疗保健支出面临的巨大压力。如此沉重的经济负担导致了严格的报销政策和市场进入限制，儘管人们对这些创新技术的治疗效果寄予厚望，但实际上却阻碍了商业性发展。

市场趋势

随着人工智慧（AI）融入奈米颗粒设计，癌症奈米药物的研发正经历一场根本性的变革。这种从试验的合成方法到预测性计算建模的转变，有效解决了奈米载体设计固有的复杂性。在这个领域，即使是微小的成分变化也会显着影响治疗效果和毒性，而利用机器学习演算法可以在实际製造之前模拟奈米颗粒与生物环境的相互作用，从而优化药物负载量和靶向精度。计算效率的提升显着加快了药物发现进程。如同News-Medical.net网站2025年9月发表的题为「AI引导平台提升治疗性奈米颗粒的设计与效率」的报导所述，研究人员利用AI驱动模型，将奈米颗粒的製备成功率提高了42.9%，远超标准方法，充分展现了该技术克服製剂瓶颈的能力。

同时，市场正经历着向免疫奈米疗法的关键转型，其显着特征是脂质奈米颗粒（LNP）的应用范围不断扩大，从感染疾病疫苗扩展到个人化癌症治疗。这一趋势强调开发先进的LNP载体，旨在将mRNA癌症疫苗和基因编辑有效载荷直接递送至肿瘤部位或免疫细胞，从而诱导强效的全身性免疫反应。这些平台的商业性潜力正推动着产业进行大量投资，旨在提高核酸递送系统的稳定性和组织特异性。这项转型的经济规模显而易见，预计到2032年，全球脂质奈米颗粒市场规模将达到23亿美元。 2025年9月，赢创宣布与Etris建立策略伙伴关係。这主要得益于肿瘤领域对核酸疗法的需求不断增长。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球癌症奈米技术市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（奈米颗粒、奈米纤维、奈米棒、石墨烯、奈米流体装置、其他）
  • 依应用领域（乳癌、胃癌、肺癌等）
  • 依最终使用者（诊断、治疗、治疗诊断）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美癌症奈米技术市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲癌症奈米技术市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区癌症奈米技术市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲癌症奈米技术市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲癌症奈米技术市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球癌症奈米技术市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Abbott Laboratories Ltd.
• GE Healthcare Inc.
• Combimatrix Corporation.
• Mallinckrodt Plc
• Sigma-Tau Pharmaceuticals Inc.
• Merck and Company Inc.
• Pfizer, Inc.
• Nanosphere, Inc.
• Celgene Corporation
• Teva Pharmaceutical Industries

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cancer Nanotechnology Market is projected to expand significantly, rising from a valuation of USD 38.05 Billion in 2025 to USD 65.05 Billion by 2031, reflecting a compound annual growth rate of 9.35%. This sector focuses on utilizing nanoscale devices and particles to achieve high-precision diagnosis, imaging, and treatment of malignancies. Key growth drivers include the urgent demand for targeted drug delivery systems capable of minimizing the systemic toxicity associated with traditional chemotherapy, alongside the critical need for early detection capabilities. This upward trajectory is further underpinned by the increasing incidence of cancer; according to the American Cancer Society, the number of new cancer diagnoses in the United States was projected to surpass 2 million for the first time in 2024, highlighting the immediate necessity for the enhanced therapeutic efficacy provided by nanomedicine.

Despite these advancements, the market faces significant hurdles due to the high costs associated with development and treatment, which create substantial financial barriers to entry. Additionally, regulatory complexities related to the safety of nanomaterials often result in prolonged approval processes. The economic burden on patients is profound; the American Association for Cancer Research reported in 2024 that over 40% of cancer patients in the United States deplete their life savings within just two years of commencing treatment. This financial toxicity poses a serious threat to the widespread adoption of these advanced technologies and could potentially constrain overall market growth.

Market Driver

A primary engine for market acceleration is the increase in strategic collaborations within the pharmaceutical industry, which facilitates the commercialization of complex nanomedicine platforms. Major pharmaceutical companies are actively pursuing mergers and acquisitions to incorporate advanced targeted delivery mechanisms into their oncology pipelines, thereby securing the necessary technical infrastructure for clinical success. These partnerships enable firms to utilize proprietary synthetic biology and conjugation technologies to refine the precision of therapeutic agents. This trend of consolidation was clearly demonstrated when Johnson & Johnson expanded its targeted oncology capabilities; according to a January 2024 announcement regarding the "Johnson & Johnson to Acquire Ambrx" deal, the company entered a definitive agreement valued at approximately $2.0 billion to obtain Ambrx Biopharma's proprietary platform for next-generation antibody-drug conjugates.

Concurrently, a surge in government funding and private capital for research and development is acting as a vital catalyst for innovation in diagnostic and therapeutic nanotechnology. Public sector initiatives play a crucial role in de-risking early-stage technologies and supporting projects designed to enhance tumor visualization and surgical outcomes through advanced imaging. This financial backing is illustrated by recent federal grants aimed at revolutionizing cancer surgery; according to a September 2024 White House "Fact Sheet," the Advanced Research Projects Agency for Health (ARPA-H) awarded $150 million to teams developing novel technologies, such as microscopic imaging systems, to increase surgical precision. This influx of capital addresses a growing global need driven by long-term epidemiological forecasts; the World Health Organization reported in 2024 that the International Agency for Research on Cancer expects the global cancer burden to exceed 35 million new cases by 2050, creating an urgent mandate for scalable nanotechnological solutions.

Market Challenge

The expansion of the Global Cancer Nanotechnology Market is directly impeded by the exorbitant costs associated with development and treatment, which establish significant financial obstacles. The creation of nanoscale particles demands intricate engineering and precision manufacturing, resulting in research and development expenses that are considerably higher than those for conventional pharmaceuticals. These capital-intensive requirements discourage investment from smaller biotechnology firms and heighten financial risks for established entities, often leading to delays in moving promising nanomedicines from clinical trials to commercial availability.

As a result, these elevated development costs are passed on to the final market price, placing a severe economic strain on both patients and healthcare systems. This financial burden limits the widespread adoption of advanced nanotherapeutics, as insurers and public health programs struggle to incorporate these costly treatments into their existing budgets. According to the European Federation of Pharmaceutical Industries and Associations, the direct costs of cancer care across Europe reached €146 billion in 2023, highlighting the immense pressure on healthcare expenditures. Such intense financial toxicity leads to strict reimbursement policies and restricted market access, effectively stifling the commercial growth of these innovative technologies despite their therapeutic promise.

Market Trends

The development of cancer nanomedicines is being fundamentally transformed by the integration of artificial intelligence into nanoparticle design, moving away from trial-and-error synthesis toward predictive computational modeling. This shift addresses the inherent complexity of engineering nanoscale carriers, where even minor compositional changes can drastically affect therapeutic efficacy and toxicity. By employing machine learning algorithms, researchers can simulate interactions between nanoparticles and biological environments to optimize drug loading and targeting precision prior to physical manufacturing. This computational efficiency significantly speeds up the discovery pipeline; as reported by News-Medical.net in a September 2025 article titled "AI-guided platform improves design and efficiency of therapeutic nanoparticles," researchers using an AI-driven model realized a 42.9% increase in successful nanoparticle formation rates compared to standard methods, confirming the technology's ability to resolve formulation bottlenecks.

In parallel, the market is undergoing a decisive transition toward immuno-nanomedicine, characterized specifically by the expansion of lipid nanoparticles (LNPs) from infectious disease vaccines to personalized oncology applications. This trend emphasizes the engineering of sophisticated LNP vehicles designed to deliver mRNA cancer vaccines and gene-editing payloads directly to tumor sites or immune cells, thereby eliciting a potent systemic response. The commercial potential of these platforms is stimulating significant industrial investment aimed at improving the stability and tissue-specificity of nucleic acid delivery systems. The economic scale of this shift is clear; according to a September 2025 announcement by Evonik regarding their strategic partnership with Ethris, the global lipid nanoparticle market is projected to reach $2.3 billion by 2032, largely fueled by the rising demand for nucleic acid-based therapies in the oncology sector.

Key Market Players

• Abbott Laboratories Ltd.
• GE Healthcare Inc.
• Combimatrix Corporation.
• Mallinckrodt Plc
• Sigma-Tau Pharmaceuticals Inc.
• Merck and Company Inc.
• Pfizer, Inc.
• Nanosphere, Inc.
• Celgene Corporation
• Teva Pharmaceutical Industries

Report Scope

In this report, the Global Cancer Nanotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Nanotechnology Market, By Type

• Nanoparticles
• Nanofibers
• Nanorods
• Graphene
• Nanofluidic Devices
• Others

Cancer Nanotechnology Market, By Application

• Breast Cancer
• Stomach Cancer
• Lung Cancer
• Others

Cancer Nanotechnology Market, By End User

• Diagnostics
• Therapeutics
• Theranostics

Cancer Nanotechnology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Nanotechnology Market.

Available Customizations:

Global Cancer Nanotechnology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Nanotechnology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Nanoparticles, Nanofibers, Nanorods, Graphene, Nanofluidic Devices, Others)
  • 5.2.2. By Application (Breast Cancer, Stomach Cancer, Lung Cancer, Others)
  • 5.2.3. By End User (Diagnostics, Therapeutics, Theranostics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cancer Nanotechnology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cancer Nanotechnology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Cancer Nanotechnology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Cancer Nanotechnology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Cancer Nanotechnology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cancer Nanotechnology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Cancer Nanotechnology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Cancer Nanotechnology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Cancer Nanotechnology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Cancer Nanotechnology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Cancer Nanotechnology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cancer Nanotechnology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Cancer Nanotechnology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Cancer Nanotechnology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Cancer Nanotechnology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Cancer Nanotechnology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Cancer Nanotechnology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cancer Nanotechnology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Cancer Nanotechnology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Cancer Nanotechnology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Cancer Nanotechnology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cancer Nanotechnology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Cancer Nanotechnology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Cancer Nanotechnology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cancer Nanotechnology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GE Healthcare Inc.
• 15.3. Combimatrix Corporation.
• 15.4. Mallinckrodt Plc
• 15.5. Sigma-Tau Pharmaceuticals Inc.
• 15.6. Merck and Company Inc.
• 15.7. Pfizer, Inc.
• 15.8. Nanosphere, Inc.
• 15.9. Celgene Corporation
• 15.10. Teva Pharmaceutical Industries

16. Strategic Recommendations

17. About Us & Disclaimer